V
VIRIOS THERAPEUTICS LLC
NASDAQ: VIRI (Virios Therapeutics, Inc.)
Kemas kini terakhir: 12 jam lalu0.178
-0.01 (-3.58%)
| Penutupan Terdahulu | 0.185 |
| Buka | 0.185 |
| Jumlah Dagangan | 417,718 |
| Purata Dagangan (3B) | 1,127,908 |
| Modal Pasaran | 4,940,906 |
| Harga / Buku (P/B) | 1.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2024 - 15 Nov 2024 |
| EPS Cair (TTM) | -0.230 |
| Nisbah Semasa (MRQ) | 7.27 |
| Aliran Tunai Operasi (OCF TTM) | -4.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.43 M |
| Pulangan Atas Aset (ROA TTM) | -67.76% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Virios Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.6 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -1.7 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.65 |
|
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”) and Long-COVID (“LC”). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.74% |
| % Dimiliki oleh Institusi | 3.60% |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |